Pulsed electromagnetic fields may be effective for the management of primary

2 osteoporosis: a systematic review and meta-analysis

3

4	Siyi Zhu ^{a,b} , Yi Li ^{a,b} , I	Liqiong Wang ^{a,b} , Jinming Huang ^{a,b} , Kangping Song ^{a,b} , Xinling Gan ^{a,b} ,
5	Xiaona Xiang ^{a,b} , Che	engqi He ^{a,b*} , Lin Yang ^{a,b*}
6		
7	^a Rehabilitation Medie	cal Center, West China Hospital, Sichuan University, Chengdu, Sichuan,
8	China.	
9	^b Rehabilitation Medi	cine key laboratory of Sichuan Province, West China Hospital, Sichuan
10	University, Chengdu	, Sichuan, China.
11		
12	*Corresponding auth	or: Dr. Chengqi He or Dr. Qiang Gao or Dr. Lin Yang at the Rehabilitation
13	Medical Center, Wes	t China Hospital, Sichuan University, No. 37 Guoxue Alley, Wuhou
14	District, 610041, Che	engdu, China. Email: hxkfhcq@126.com (CH) or 5648197@qq.com (LY).
15		
16	Abbreviated title:	Pulsed electromagnetic fields for primary osteoporosis
17	Key words:	Osteoporosis, Electromagnetic Fields; Bone Density; Physical Therapy
18		Modalities; Disability Evaluation
19	Word Count:	350 words (Abstract)
20		3735 words (Main text)
21		

22 ABSTRACT

- 23 **Objective:** To investigate the effectiveness of pulsed electromagnetic fields (PEMFs) for the
- 24 management of primary osteoporosis in older adults.
- 25 **Design:** Systematic review and meta-analysis.
- 26 **Data Sources:** MEDLINE, EMBASE, Web of Science, CENTRAL and CCTR, Physiotherapy
- 27 Evidence Database, CNKI, VIP, Wan Fang, ClinicalTrials.gov and Current controlled trials from
- the inception dates to April 30, 2021.
- 29 Eligibility criteria for study selection: Randomised controlled trials or quasi-randomised trials
- 30 examining the effects of PEMFs compared to placebo or sham or other agents for the
- 31 management of primary osteoporosis (including those with previous fractures).
- 32 Data extraction and synthesis: Two independent reviewers extracted data. Primary outcomes
- 33 were bone mass and number of incident fractures. Secondary outcomes were functional
- 34 assessments, quality of life, and adverse events. Risk of bias was assessed with the Cochrane
- 35 Collaboration's tool and certainty of evidence with the grading of recommendations assessment,
- 36 development and evaluation (GRADE) framework. A random effects model was used to calculate
- 37 mean differences and 95% confidence intervals.
- 38 Results: Eight trials including 396 participants met the inclusion criteria. Low certainty evidence 39 showed that PEMFs was non-inferior to conventional pharmacological agents in preventing the 40 decline of Bone Mineral Density (BMD) at the lumbar (MD 0.01; CI -0.04 to 0.06) and femur 41 neck (MD 0.01; CI -0.02 to 0.04), and improving balance function measured by Berg Balance 42 Scale (BBS) (MD 0.01; CI -0.09 to 0.11) and Timed Up and Go test (MD -0.04; CI -0.80 to 0.72),
- 43 directly after intervention. The similar effects were observed in BMD and BBS at 12- and 24-
- 44 weeks follow-up from baseline with moderate certainty evidence. Very low certainty evidence
- 45 showed that PEMFs (versus exercise) had small but significant effect on BMD at the femur neck
- 46 (MD 0.10; CI 0.01 to 0.20), and no effect on BMD at the lumbar (MD 0.15; CI -0.04 to 0.35).
- 47 **Conclusion:** PEMFs had positive effects non-inferior to first-line treatment on BMD and balance
- 48 function in older adults with primary osteoporosis, but with low to very low certainty evidence
- 49 and short-term follow-ups. There is a need for high-quality randomised controlled trials
- 50 evaluating PEMFs for the management of primary osteoporosis.
- 51 **Registration:** PROSPERO CRD42018099518.
- 52

53 INTRODUCTION

54 Osteoporosis is a systemic and multifactorial skeletal disorder characterized by low bone mineral 55 density and skeletal fragility that occur with aging, with a consequent increase of susceptibility to 56 low-trauma fractures¹. The most prevalent symptoms of osteoporosis are fractures at vertebrae, proximal femur (hip), and wrist affecting patients' physical function and quality of life. It is 57 58 estimated that over 200 million people worldwide are affected by osteoporosis, accounting for 8.9 million fractures annually². The possibility of osteoporotic fractures exceeds 40% and the 59 probability of hip fracture alone could target 20% in white female population over 50 years old 3 . 60 In China, a higher incidence of hip fractures in men than in women was reported ⁴. Each year, 61 62 osteoporotic fractures account for over 432,000 hospitalizations and 2.5 million medical visits in the USA ⁵. The treatment costs for fractures were recorded at nearly \$17 billion in the USA in 63 2005⁶, and €31.7 billion in Europe in 2000⁷. Therefore, osteoporosis has been identified as a 64 major health burden globally by WHO, due to its high prevalence, disability rate, related 65 mortality and poor quality of life⁸. 66

67 Rehabilitation interventions given its important roles in modifying risk factors related to fractures, 68 restoring function and improving quality of life are frequently recommended as an option in the nonpharmacological management of osteoporosis ^{9,10}. Pulsed electromagnetic fields (PEMFs) at a 69 70 specific intensity and frequency have been proved effective in attenuating bone loss and the relief of pain and discomfort after osteoporosis. As we reviewed elsewhere ¹¹, PEMFs were found to be 71 72 positive at promoting bone formation by stimulating the formation and differentiation of 73 osteoblasts, and negative at inhibiting the function of osteoclasts in bone resorption. Experimental studies suggest that PEMFs may exert effects on Ca²⁺-related receptors on the bone 74 cell membrane which play a regulatory role in the maintenance of bone remodelling ¹². Further, 75 76 the exposure of PEMFs could influence the physiopathology of osteoporosis by targeting 77 inflammation and potentially relieving pain via these regulatory processes and improvements in bone remodeling 13 . 78

PEMFs have been widely used as an clinical option for the management of pain and discomfort related to osteoporosis since the introduce of its usage for non-union fractures was approved by FDA in 1979¹⁴. However, clinical trials evaluating the effectiveness of PEMFs have been conducted with inconsistent results, to which parameters of PEMFs used in studies, follow-up time points and clinical settings differ across studies may lead¹¹. In order to expand upon the

84 current knowledge on whether PEMFs is an effective physical agent for osteoporosis clinically, a

85 systematic review and meta-analysis of clinical trials was performed to compare PEMFs with

- 86 placebo or sham or other agents for the management of primary osteoporosis in older adults.
- 87

88 METHODS

This systematic review and meta-analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions ¹⁵ and reported based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (PRISMA) ¹⁶. The protocol of this study is available in PROSPERO (CRD42018099518) ¹⁷.

93

94 Identification and selection of studies

95 We searched the MEDLINE (via Ovid), EMBASE (via Ovid), Web of Science, CENTRAL and 96 CCTR (via The Cochrane Library), Physiotherapy Evidence Database (via PEDro website), 97 CNKI, VIP, Wan Fang, ClinicalTrials.gov (https://www.clinicaltrials.gov/) and Current 98 controlled trials (www.controlled-trials.com) from the inception dates to December 9, 2018, 99 using the keywords *pulsed electromagnetic fields* and *osteoporosis*. The Open Grey 100 (http://www.opengrey.eu/) was searched for the Grey Literature research. The detailed electronic 101 search strategies are provided in Supplementary Appendix I. An additional search was performed under a mechanism of living systematic review ¹⁸ to identify recently published randomized 102 103 clinical trials (RCTs) from December 10, 2018 to April 30, 2021 using the databases and 104 keywords described above. The whole procedure was assisted by a librarian from Sichuan 105 University.

106 Randomised controlled trials or quasi-randomised trials examining the effects of PEMFs 107 compared to placebo or sham or other agents for the management of primary osteoporosis 108 (including those with previous fractures) were included if they met the inclusion criteria listed in 109 Box 1. Studies were excluded if the study population had a diagnosis of corticosteroid-induced 110 osteoporosis or other secondary osteoporosis (e.g., rheumatoid arthritis), studies where 111 participants had a history of hip replacement or surgery related with osteoporotic fractures, the 112 study type was observational studies, review articles, abstracts, conference reports and book 113 chapters.

114 A three-stage screening methodology was performed to select relevant RCTs for this review.

Primarily, all titles were screened by one reviewer (SYZ) for eligibility and irrelevant papers were excluded accordingly. Secondary, two reviewers (YL and LQW or KPS) independently reviewed each study title and abstract. Thirdly, two independent reviewers (XNX and JMH or XLG) accessed the full text to assess against the eligibility criteria for each potentially eligible study. A third reviewer (CQH or LY) was involved for any disagreement.

120

121 Assessment of characteristics of studies

122 Quality assessment

The risk of bias was assessed by using the Cochrane Collaboration's 'Risk of bias' tool ¹⁵. Seven 123 124 key domains were assessed by two reviewers (SYZ and LQW): 1) the randomization sequence 125 generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of 126 outcome assessment, 5) incomplete outcome data, 6) selective reporting, and 7) other bias. The 127 included studies were graded as low, unclear, or a high risk of bias. Methodological quality was assessed with the use of Physiotherapy Evidence Database (PEDro) tool ¹⁹, which was proved 128 reliable ²⁰ and valid ²¹. Each criterion in the PEDro scale with a range of 0-10 was scored 1 129 130 ("yes") or 0 ("no, don't know/unclear"). Generally, trials with a PEDro summary score of over five. were considered to have adequate methodological quality ²². Finally, we used Grading of 131 Recommendations, Assessment, Development and Evaluations (GRADE)²³ to describe the 132 133 overall quality of the body of evidence.

134

135 Participants

To be included, studies involved participants were healthy older adults (including those with previous fractures) aged over 50 years with primary osteoporosis ²⁴, recognized by two distinct types ²⁵: 1) type I occurred in postmenopausal women; 2) type II, known as senile osteoporosis, occurred in both men and women.

140

141 Interventions

All RCTs applying electromagnetic fields with pulsed signal and extremely low frequencies (between 5 and 300 Hz) for the management of primary osteoporosis were included. The parameters (frequency and intensity) of PEMFs, sessions per week and total duration of the treatment period were recorded to describe the interventions.

146

147 *Outcome measures*

148 All outcomes were continuous data and recorded as the percent change from baseline to post-149 intervention and different follow-up timepoints. To be included, trials had to provide original 150 data or sufficient information about at least one of outcomes on bone mass, number of incident 151 fractures, self-reported data on the changes in balance and quality of life, physical activity and 152 function, and adverse events. Primary outcomes were bone mass (e.g., Bone Marrow Density or 153 Bone Mineral Content) immediately post-intervention and at follow-ups, and number of incident 154 fractures. Secondary outcomes were functional assessments (e.g., Berg Balance Scale, Timed Up 155 and Go test), quality of life (e.g., EuroQoL (EQ 5D)) and adverse events (e.g., falls and death).

156

157 Data extraction and analysis

Two independent reviewers (SYZ and YL) extracted the following information from eligible studies: lead author; year of publication; original country; subject characteristics; study design; treatment information; intervention protocol; outcome measures; raw outcome data; follow-up period and other relevant information. Disagreements were resolved by consensus.

162 All meta-analyses were performed using analysis was performed using Review Manager 163 (RevMan) software (The Cochrane Collaboration, version 5.4). For each included study, the 164 mean difference (MD) of percentage change with 95% confidential intervals (CIs) was calculated 165 when the outcome measures were consistent across studies or else the standard mean difference 166 (SMD) was calculated instead for continuous outcomes (reporting mean and standard deviation 167 (SD) or standard error (SE) of the mean). If the MD was not reported, it was calculated as the 168 change between values of the baseline and post-intervention. In the case that the value of SD 169 (SD_{diff}) was not reported, it was obtained 1) by multiplying SEs of means by the square root of 170 the sample size when standard errors (SEs) of the means were reported, or 2) with SDs at the 171 baseline (SD_{baseline}) and post-intervention SD (SD_{post}) in addition to the within-groups bivariate 172 correlation coefficient (r) 26 :

$$SD_{diff} = \sqrt{SD_{baseline}^2 + SD_{post}^2 - (2 \times r \times SD_{baseline} \times SD_{post})}$$

173 The I^2 statistic was employed for evaluating heterogeneity and a standard Chi² test was employed 174 for detecting whether significant heterogeneity existed. Heterogeneity was statistically significant

175 at P < 0.10 after due consideration of I^2 statistic, of which a value greater than 50% was 176 considered substantial heterogeneity ²⁷. The random-effects model was applied where the 177 evidence of heterogeneity was found.

178 The comparison was established between PEMFs and placebo control or exercise in the meta-179 analysis. The subgroup analysis was conducted to detect the effectiveness relative to different 180 follow-up timepoints (postintervention; follow-up at 12, 24 weeks from baseline). To evaluate the 181 quality and consistency of pooled results, the sensitivity analysis was conducted by deleting each 182 included study. Where the data allowed, assessment of publication bias was performed. All tests 183 were two-tailed, and P < 0.05 was considered statistically significant.

184

185 **RESULTS**

186 Flow of studies through the review

In total, 806 articles were identified by our search, of which 124 duplicate articles were removed.
Based on title and abstract screening, 632 of these articles were excluded. Full texts of 50 articles
were read, a further 42 articles were excluded, remaining 8 articles included in the data extraction
and analysis of the review (Figure 1) ²⁸⁻³⁵.

191

192 Characteristics of studies

193 Quality

All included studies achieved PEDro scores over 5, among which five studies achieved the score over 8 (Table 1)^{28,29,31-33}. Of the 8 included studies, 2 studies were rated as 'low risk of bias' in all

domains^{31,32}, and other studies were classified as 'unclear risk of bias' for at least 1 aspect or 'high risk of bias' for at least 2 aspects. In results of GRADE, the quality of the evidence for the comparison between PEMFs versus placebo control was low or moderate, and that for the comparison between PEMFs versus exercise was very low. The results of the risk of bias and GRADE are presented in the Supplementary Tables and Figures.

201

202 Participants

In total, data were extracted for 396 participants, comprising 183 participants in PEMFs group and 213 participants in placebo control (alendronate/pharmacological therapy) or exercise group.

205 Mean age ranged from 56.3 to 70 years, with a gender ratio of 49 to 347. Participant 206 characteristics are detailed in Table 2.

207

208 Intervention

The frequency and intensity of PEMFs exposure varied at 8-100 Hz and 1.2-5 mT separately. A range of 30-36 PEMFs sessions, with 30-60 min/session, were prescribed for participants, and 4 to 72 weeks follow-up were conducted across all studies. Control intervention types included first-line pharmacological agents (e.g., Alendronate, intake of Vitamin D and Calcium) and exercise (e.g., whole body vibration and resistance training). The intervention characteristics of the included studies are detailed in the Table 2.

215

216 *Outcome measures*

The outcome measures in each study with the categories of bone mass and functional assessments are detailed in Table 2.

219

220 Effect of intervention I: PEMFs versus control group

221 Bone Mineral Density (BMD)

Five studies (study population, N=248) $^{28,30-33}$ and three studies (study population, N=124) 222 ^{30,32,33} reported data on percentage change in BMD at the lumbar and femur neck respectively 223 224 after intervention directly (Figure 2). Low certainty evidence showed that PEMFs has no effect 225 on BMD at the lumbar (MD 0.01; CI -0.04 to 0.06) and femur neck (MD 0.01; CI -0.02 to 0.04) with no statistically significant heterogeneity (lumbar: $I^2 = 0\%$, P =0.48; femur neck: $I^2 = 0\%$, P = 226 0.79). Two studies (study population, N=125) ^{31,32} performed follow-ups at 12 and 24 weeks from 227 228 baseline on percentage change in BMD at the lumbar (Figure 2). Moderate certainty evidence 229 showed that there is no statistically significant effect on BMD at the lumbar at the 12 weeks 230 follow-up (MD -0.01; CI -0.28 to 0.25) and the 24 weeks follow-up (MD -0.02; CI -0.30 to 0.26) 231 with no statistically significant heterogeneity (12 weeks: $I^2 = 0\%$, P = 1.00; 24 weeks: $I^2 = 0\%$, P 232 = 0.98). No significant changes in heterogeneity and overall effect were observed in the 233 sensitivity analysis.

234

235 Berg Balance Scale (BBS)

Three studies (study population, N=168) ^{31,32,35} conducted the assessment of BBS after 236 237 intervention directly (Figure 3). Low certainty evidence showed that there is no statistically 238 significant effect on percentage change in BBS (MD 0.01; CI -0.09 to 0.11) with no statistically significant heterogeneity ($I^2 = 0\%$, P = 1.00). Two studies (study population, N=125) ^{31,32} carried 239 out follow-ups at 12 and 24 weeks from baseline on percentage change in BBS (Figure 3). 240 241 Moderate certainty evidence showed that no statistically significant effect is detected on BBS at 242 the 12 weeks (MD 0.00; CI -0.13 to 0.14) and 24 weeks follow-up (MD -0.00; CI -0.15 to 0.14) with evidence of no statistically significant heterogeneity (12 weeks: $I^2 = 0\%$, P = 0.99; 24 weeks: 243 244 $I^2 = 0\%$, P = 0.99). No significant changes in heterogeneity and overall effect were observed in 245 the sensitivity analysis.

246

247 Timed Up and Go (TUG) test

Two studies (study population, N=127) 31,35 assessed the percentage change in TUG test after intervention directly (Figure 3). Low certainty evidence showed that there is no statistically significant effect on TUG (MD -0.04; CI -0.80 to 0.72) with no statistically significant heterogeneity (I² = 0%, P = 0.97). No significant changes in heterogeneity and overall effect were observed in the sensitivity analysis.

253

254 Effect of intervention II: PEMFs versus exercise group

Three studies (study population, N=110) ^{29,33,34} investigated the effect of PEMFs on percentage 255 256 change in BMD at the lumbar and femur neck respectively after intervention directly (Figure 4). 257 Very low certainty evidence showed that PEMFs has small but significant effect on BMD at the 258 femur neck (MD 0.10; CI 0.01 to 0.20), and no effect on BMD at the lumbar (MD 0.15; CI -0.04 259 to 0.35), both with no statistically significant heterogeneity respectively (femur neck: $I^2 = 28\%$, P = 0.25; $I^2 = 47\%$, P = 0.15). In the sensitivity analysis, one study ²⁹was found to be a contributor 260 261 to results of non-significant heterogeneity and the effect on BMD at the femur neck. After 262 excluding the study, the heterogeneity was reduced to 0% (femur neck: P = 0.96; P = 0.86), and 263 the small but significant effect on BMD at the femur neck was eliminated (MD 0.00; CI -0.15 to 264 0.16).

265

266 **DISCUSSION**

267 This systematic review and meta-analysis of 8 studies involving 396 participants demonstrated 268 PEMFs as a physical therapy was non-inferior to conventional pharmacological agents in 269 preventing the decline of BMD and balance function for the management of primary osteoporosis 270 in older adults. Meanwhile, we also found that PEMFs might be slightly more effective in 271 increasing BMD than exercise. According to our knowledge, no systematic review and meta-272 analysis was initiated before, except one network meta-analysis exploring effects of nonpharmacological interventions including PEMFs on balance function only ³⁶, and several 273 narrative reviews including clinical studies were retrieved ^{11,37,38}. Our results are in consistent 274 with findings from previous reviews^{11,36,37} that PEMFs achieved positive effects on BMD and 275 276 balance function for older adults with primary osteoporosis, implicating that PEMFs may 277 potentially become a promising treatment option.

278 Bisphosphonates and exercise were both identified as the first-line interventions for the management of osteoporosis in the latest evidence-based guideline ¹⁰. Our study established 279 280 comparisons between PEMFs and active placebo or exercise based on groups set by included 281 studies, and sub-group analysis was stratified by different intervals between the baseline, post-282 intervention, and follow-ups. BMD, as a surrogate measure for therapeutic effectiveness, can be 283 assessed by various methods, among which dual x-ray absorptiometry (DXA) was proved to be reliable in the diagnosis of osteoporosis and have relatively good responsiveness in RCT ^{39,40}. 284 285 Our study demonstrated that there was no difference between PEMFs and active placebo in 286 improving BMD at the lumbar and femur neck in all sub-group meta-analysis, which suggests 287 PEMFs is nearly effective as pharmacological agents for osteoporosis, and the effect could last 288 for at least 24 weeks. Moreover, the effects of PEMFs versus exercise on BMD at the lumbar was 289 not significant, while that was detected as small but significant on BMD at the femur neck. Our results were considered fairly stable as the sensitivity analysis only detected one study ²⁹affecting 290 291 the heterogeneity and effect of PEMFs versus exercise on BMD at the femur neck. This is likely 292 due to variations in exercise characteristics (e.g., duration, training load and training volume). 293 Therefore, this part of results should be interpreted with caution.

Impaired balance function is an important risk factor increasing the incidence of falling and fracture, which is modifiable by balance-improving interventions ⁴¹. In line with results on BMD, no statistically significant difference was observed for balance function measured by BBS and TUG after the intervention of PEMFs versus active placebo. In the sub-group analysis, the effect

298 of PEMFs on BBS at 12, 24 weeks follow-up was also not statistically significant, confirming 299 that PEMFs is as effective as conventional pharmacological agents in improving balance function which could last for 24 weeks. In consistent with a previous systematic review 36 , it reported that 300 301 PEMFs exert positive effect on BBS and TUG tests reflecting balance function. However, the 302 network meta-analysis was conducted to further compare the effects of five interventions on 303 balance function with the conclusion that balance and strength training was better than other 304 interventions. Only one study using data on PEMFs was included in the analysis, compared to 305 that we included 3 studies, and no study was ever conducted to directly compare the effect of 306 PEMFs versus other non-pharmacological interventions on balance function, combining these 307 two may explain, in part, the conflicting results. Furthermore, our sensitivity analysis detecting 308 no changes in levels of heterogeneity and effect confirmed our results as relatively robust.

309 To overcome the shortcomings of the "statistically significant difference", the minimum 310 clinically important difference (MCID) defined as "the smallest change that is important to patients" is employed to generate a threshold value for such change ⁴². Any patient whose 311 312 responses help them reach the MCID threshold is considered as responders. Thus, a certain 313 proportion of responders to the total participants involved in a trialed intervention indicates the 314 likelihood of patients under the same condition also responding favorably to the same intervention ⁴³. However, no definite consensus reached on the MCID of BMD and balance 315 316 function. Some evidence showed that changes by 2-5% at the lumbar and 8% at the proximal femur⁴⁴, a point-drop in BBS associated with a 3-4% increase in risk of falling⁴⁵, and an 317 improvement of 2-3 seconds in TUG test were considered as MCID for the older population ⁴⁶. In 318 319 our study, no study included used the MCID and responder rate to evaluate the effect of PEMFs, 320 thus, it is hard to determine the clinical importance of improvements achieved by PEMFs on 321 BMD and balance function compared with placebo and exercise. Furthermore, the successful 322 treatment of osteoporosis is prevention of fractures, while no treatment can completely eliminate fracture risk ¹⁰. Although a certain increase in BMD and the improvement in balance function for 323 324 osteoporosis may result in a reduction in fracture risk, no risk and number of incident fracture 325 were reported in studies included in our review. Therefore, studies with reporting measures of 326 MCID, fracture risk and incidence in the future are required to further confirm that the effect of 327 PEMFs in treating osteoporosis is of clinical importance to clinicians and patients.

328 This review has several strengths. To date, we are the first to conduct a systematic review and

329 meta-analysis to explore the effect of PEMFs on BMD and balance function for primary 330 osteoporosis. Secondary, the results of our study were fairly stable due to studies included were 331 of appropriate methodological quality, and no significant heterogeneity was found in the analysis. 332 Furthermore, a key finding of this review was that PEMFs as an intervention alone achieved an 333 effect non-inferior to first-line treatment (pharmacological agents and exercise) on improvements 334 in BMD and balance function for older adults with primary osteoporosis. At last, a librarian 335 familiar with the development of searches and a mechanism of living systematic review were 336 involved over a course of 3 years to ensure no study was missed in compliance with the study 337 protocol.

338 There are several limitations to this review that deserve consideration. The primary limitation of 339 our review was the limited number of included studies with only 8 studies comprising of 396 340 participants for the analysis, from which the level of evidence generated were moderate to very 341 low. In some sub-group analyses, only 2-3 studies were included from which some uncertainty in 342 the results interpretation may exist based on data extracted. In addition, as the maximum PEMF 343 treatment session lasted for 16 weeks and the longest follow-up was 24 weeks for the analysis, 344 the error among the minimum percentage change in BMD and balance function may stay undetectable and further deepened the uncertainty ⁴⁴. Furthermore, the clinical relevance of the 345 346 findings was limited, combined with no study reported data on MCID, responder rate and incident fracture and only two studies ^{31,32}included used intention-to-treat (ITT) analysis. 347 According to accumulated evidence ^{11,47}, the parameters of non-pharmacological interventions, 348 349 including intensity, frequency, and duration, were critical to impact changes in outcome measures 350 for osteoporosis, while our study could not conduct the sub-group analysis based on different 351 parameters due to limited information retrieved. Another potential limitation was the systematic 352 search was limited to English and Chinese manuscripts available in full text, and some relevant 353 trials may be missed.

354

355 CONCLUSION

In summary, moderate to very low certainty evidence showed that PEMFs as an intervention alone has positive effects non-inferior to first-line treatment (pharmacological agents and exercise) on BMD and balance function in older adults with primary osteoporosis and should be considered as a promising option in the management of osteoporosis. Although uncertainty about responses

360 to the intervention and changes in outcome measures may be existed but undetectable, our 361 findings may still be fairly stable as we consistently found similar results in the primary and 362 sensitivity analyses. For further deeply confirming the effect of PEMFs for osteoporosis, adding 363 endpoints like fracture risk and incidence, and outcome measures like MCID and responder rate 364 to the core collection are necessary. In the future, researchers planning a PEMFs study should 365 optimize the study design, with taking factors not limited to undetectable errors under outcomes, 366 parameters of interventions, longer follow-up period, larger sample size and ITT analysis into 367 consideration, to generate high certainty evidence.

368

369 **DECLARATIONS**

370

371 Acknowledgements

We are grateful for the partnership and support from the library of Sichuan University for the

development of search strategy, also and the clinical research and statistics office of West China

- Hospital for data processing and analysis.
- 375

Funding

377 This study was supported by the National Natural Science Foundation (81972146 to Chengqi He,

and 82002393 to Siyi Zhu), the Department of Science and Technology of Sichuan Province

379 (2020YJ0210 to Chengqi He, 2021YFS0004 and 2021YJ0424 to Siyi Zhu), China Postdoctoral

380 Science Foundation (2020M673251), Health Commission of Sichuan Province (20PJ034), and

381 West China Hospital of Sichuan University (2019HXBH058 to Siyi Zhu). The funders played no

role in the design, conduct, or reporting of this study.

383

384 Availability of Data and Materials

- 385 Not applicable
- 386

387 Authors' contributions

- 388 All authors have made substantial contributions to the study design. SYZ and YL have
- 389 contributed to the ongoing data collection. All listed authors have contributed to the drafting of
- the manuscript.

391

392 Competing interests

- 393 The authors declare that they have no competing interests.
- 394

395 **REFERENCES**

- Eastell R, O'Neill TW, Hofbauer LC, et al. Postmenopausal osteoporosis. *Nature reviews Disease primers*. 2016;2:16069.
- International Osteoporosis Foundation. EPIDEMIOLOGY OF OSTEOPOROSIS AND
 FRAGILITY FRACTURES. https://www.osteoporosis.foundation/facts statistics/epidemiology-of-osteoporosis-and-fragility-fractures. Published 2021. Accessed
- 401 May 12, 2021.
- 402 3. Bessette L, Ste-Marie L-G, Jean S, et al. The care gap in diagnosis and treatment of 403 women with a fragility fracture. *Osteoporosis International*. 2008;19(1):79-86.
- 404
 4. International Osteoporosis Foundation. KEY STATISTICS FOR ASIA.
 405
 406
 406
 407
 406
 408
 409
 409
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 <l
- 4075.US D. Bone health and osteoporosis: A Report of the Surgeon General. http://www408surgeongeneral gov/library/bonehealth/content html. 2004.
- 409 6. Burge R, Dawson
 Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence
 410 and economic burden of osteoporosis related fractures in the United States, 2005–2025.
 411 Journal of bone and mineral research. 2007;22(3):465-475.
- 412 7. Kanis J, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. *Osteoporosis international*. 2005;16(3):229-238.
- 414 8. Kanis J, Group WS. Assessment of Osteoporosis at the Primary Health Care Level.
 415 Geneva. World Health Organization. 2008.
- 416 9. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. *Pharmacy*417 *and Therapeutics*. 2018;43(2):92.
- 418 10. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical
 419 Endocrinologists/American College of Endocrinology clinical practice guidelines for the
 420 diagnosis and treatment of postmenopausal osteoporosis—2020 update. *Endocrine*421 *Practice*. 2020;26:1-46.
- 422 11. Zhu S, He H, Zhang C, et al. Effects of pulsed electromagnetic fields on postmenopausal osteoporosis. *Bioelectromagnetics*. 2017;38(6):406-424.
- 424 12. Petecchia L, Sbrana F, Utzeri R, et al. Electro-magnetic field promotes osteogenic
 425 differentiation of BM-hMSCs through a selective action on Ca 2+-related mechanisms.
 426 Scientific reports. 2015;5:13856.
- 427 13. Vincenzi F, Targa M, Corciulo C, et al. Pulsed electromagnetic fields increased the anti428 inflammatory effect of A2A and A3 adenosine receptors in human T/C-28a2
 429 chondrocytes and hFOB 1.19 osteoblasts. *PloS one*. 2013;8(5):e65561.
- 43014.Andrew C, Bassett L, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively
coupled electromagnetic fields. *Science*. 1974;184(4136):575-577.
- Higgins JP, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons; 2019.
- 43416.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated435guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.

436 Sivi Z, Wei X, Hongchen H, et al. Pulsed electromagnetic fields (PEMFs) for preventing 17. and treating primary osteoporosis: systematic review and meta-analysis of randomized 437 438 controlled trials. PROSPERO 2018 CRD42018099518. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018099518. 439 440 Published 2021. Accessed May 16, 2021. 441 18. Cochrane Library. Living systematic reviews. https://community.cochrane.org/review-442 production/production-resources/living-systematic-443 reviews#:~:text=Living%20Evidence%20Network-444 ,What%20is%20a%20living%20systematic%20review%3F,the%20evidence%20(i.e.%20 445 monthly% 20searches). Published 2021. Accessed May 16, 2021. 446 Sherrington C, Herbert R, Maher C, Moseley A. PEDro. A database of randomized trials 19. 447 and systematic reviews in physiotherapy. Manual therapy. 2000;5(4):223-226. 448 Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro 20. 449 scale for rating quality of randomized controlled trials. Physical therapy. 2003;83(8):713-450 721. 451 21. de Morton NA. The PEDro scale is a valid measure of the methodological quality of 452 clinical trials: a demographic study. Australian Journal of Physiotherapy. 453 2009;55(2):129-133. 454 22. da Costa BR, Hilfiker R, Egger M. PEDro's bias: summary quality scores should not be 455 used in meta-analysis. Journal of clinical epidemiology. 2013;66(1):75-77. 456 23. Group GW. Grading quality of evidence and strength of recommendations. BMJ: British 457 Medical Journal. 2004;328(7454):1490. 458 Soen S, Fukunaga M, Sugimoto T, et al. Diagnostic criteria for primary osteoporosis: year 24. 459 2012 revision. Journal of bone and mineral metabolism. 2013;31(3):247-257. 460 25. Glaser DL, Kaplan FS. Osteoporosis: definition and clinical presentation. Spine. 461 1997;22(24):12S-16S. 462 Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. 26. 463 Cochrane handbook for systematic reviews of interventions. 2019:143-176. 464 27. Sedgwick P. Meta-analyses: what is heterogeneity? *Bmj.* 2015;350:h1435. 465 28. Abdelaal AA, Taha MM, Amin DI, Draz AH. Effect of pulsed electromagnetic therapy 466 versus low-level laser therapy on bone mineral density in the elderly with primary 467 osteoporosis: a randomized, controlled trial. Bulletin of Faculty of Physical Therapy. 468 2017;22(1):34-39. 469 29. Elsisi HFEM, Mousa GSM, ELdesoky MTM. Electromagnetic field versus circuit weight 470 training on bone mineral density in elderly women. *Clinical interventions in aging*. 471 2015;10:539. 472 Giordano N, Battisti E, Geraci S, et al. Effect of electromagnetic fields on bone mineral 30. 473 density and biochemical markers of bone turnover in osteoporosis: a single-blind, 474 randomized pilot study. Current Therapeutic Research. 2001;62(3):187-193. 475 31. Liu H, Liu Y, Yang L, Wang C, Wu Y, He C. Curative effects of pulsed electromagnetic 476 fields on postmenopausal osteoporosis. Sheng wu yi xue gong cheng xue za zhi= Journal 477 of biomedical engineering = Shengwu vixue gongchengxue zazhi. 2014;31(1):48-52. 478 Liu HF, Yang L, He HC, et al. Pulsed electromagnetic fields on postmenopausal 32. 479 osteoporosis in southwest China: A randomized, active \Box controlled clinical trial. 480 Bioelectromagnetics. 2013;34(4):323-332. 481 Shanb AA, Youssef EF, Muaidi QI, Alothman AA. Whole body vibration versus 33. 482 magnetic therapy on bone mineral density in elderly osteoporotic individuals. Journal of

483		back and musculoskeletal rehabilitation. 2017;30(4):903-912.
484	34.	Shanb A-SA, Youssef EF, El-Barkouky MG, Kamal RM, Tawfick AM. The effect of
485	54.	magnetic therapy and active exercise on bone mineral density in elderly women with
486		osteoporosis. Journal of Musculoskeletal Research. 2012;15(03):1250016.
487	35.	Wu Y-C, Xu J, Yang L, Xiong E-F, Xie W, He C-Q. The effect of low-frequency pulsed
488	55.	electromagnetic fields on balance ability of patients with post-menopausal osteoporosis.
489		Sichuan da xue xue bao Yi xue ban= Journal of Sichuan University Medical science
490		edition. 2014;45(1):116-119.
491	36.	Zhu L, Wu W, Chen M, et al. Effects of Nonpharmacological Interventions on Balance
492	201	Function in Patients with Osteoporosis or Osteopenia: A Network Meta-Analysis of
493		Randomized Controlled Trials. Evidence-Based Complementary and Alternative
494		Medicine. 2021;2021.
495	37.	Wang R, Wu H, Yang Y, Song M. Effects of electromagnetic fields on osteoporosis: a
496		systematic literature review. <i>Electromagnetic biology and medicine</i> . 2016;35(4):384-390.
497	38.	Wang T, Yang L, Jiang J, et al. Pulsed electromagnetic fields: promising treatment for
498		osteoporosis. Osteoporosis International. 2019;30(2):267-276.
499	39.	Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and
500		treatment of osteoporosis. Postgraduate medical journal. 2007;83(982):509-517.
501	40.	Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of
502		osteoporosis. Journal of bone and mineral research. 1994;9(8):1137-1141.
503	41.	Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a
504		systematic review of recent 10 years and meta-analysis. Journal of the American Medical
505		Directors Association. 2012;13(2):188. e113-188. e121.
506	42.	Stratford PW, Binkley JM, Riddle DL, Guyatt GH. Sensitivity to change of the Roland-
507		Morris back pain questionnaire: part 1. <i>Physical therapy</i> . 1998;78(11):1186-1196.
508	43.	Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically
509		important difference in pain outcome measures. Pain. 2000;88(3):287-294.
510	44.	Cranney A, Welch V, Wells G, et al. Discrimination of changes in osteoporosis outcomes.
511		The Journal of rheumatology. 2001;28(2):413-421.
512	45.	Shumway-Cook A, Baldwin M, Polissar NL, Gruber W. Predicting the probability for
513	4.5	falls in community-dwelling older adults. <i>Physical therapy</i> . 1997;77(8):812-819.
514	46.	Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for
515	47	frail elderly persons. Journal of the American geriatrics Society. 1991;39(2):142-148.
516	47.	Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in
517		postmenopausal women. Cochrane Database of Systematic Reviews. 2002(2).
518 510		
519		

- 520 Box of inclusion criteria for eligible studies
- 521 522 523

Box 1. Inclusion criteria

Design

- Randomised or guasi-randomised controlled trial
- Published in a peer-reviewed journal
- Full text available in Chinese and English

Participants

· Healthy older adults (including those with previous fractures) aged over 50 years with primary osteoporosis

Intervention

- Electromagnetic fields with pulsed signal and extremely low frequencies (between 5 and 300 Hz) Outcome measures
 - · Primary outcomes: bone mass, number of incident fractures
 - · Secondary outcomes: Functional assessments, quality of life, adverse events

Comparisons

- PEMFs versus sham/nothing
- PEMFs versus placebo/pharmacological agents
- PEMFs versus exercise/other physical agent or intervention
- PEMFs plus other intervention versus other intervention

 $5\bar{2}\bar{5}$ 526

Table 1

PEDro scores of included studies.

Study	Eligibility criteria and source	Random allocation	Conceale d allocation	Baseline comparab ility	Blind subjects	Blind therapists Blind	Blind assessors	Adequate follow-up	Intention- to-treat analysis	Between- group comparis ons	Point estimates and variability	Total score (0 to 10)
Liu Hf et al, 2013 ³²	Y	Y	Y	Y	Ν	Ν	Y	Y	Y	Y	Ŷ	9
Liu Hf et al, 2014 ³¹	Y	Y	Y	Y	Ν	Ν	Ν	Y	Y	Y	Y	8
Shanb et al, 2017 ³³	Y	Y	Y	Y	Ν	Ν	Y	Y	Ν	Y	Y	8
Shanb et al, 2012 ³⁴	Y	Y	Ν	Ν	Ν	Ν	Ν	Y	Ν	Y	Y	5
Elsisi et al, 2015 ²⁹	Y	Y	Y	Ν	Y	Y	Y	Y	Ν	Y	Y	9
Giordano et al, 2001 ³⁰	Y	Y	Ν	Y	Ν	Ν	Y	Y	Ν	Y	Y	7
Wu Yc et al, 2014 ³⁵	Y	Y	Ν	Y	Ν	Ν	Ν	Y	Ν	Y	Y	6
Ashraf et al, 2017 ²⁸	Y	Y	Y	Y	Ν	Ν	Y	Y	Ν	Y	Y	8

Table 2

Characteristics of the included studies.

	Sample	Study arms	Age (y)							up
	size	Study anns	Age (y)	Male/Female	Type of intervetion	Dose per protocol ^a	Primary	Secondary	Efficacy/Effect	up
Liu Hf et 4 al, 2013 ³²	41	1. PEMFs (n=20) 2. AL (n=21)	61.70 (1.34) 63.14 (4.32)	0/41	PEMFs	3.82 mT, 8 Hz, 40min/session for a total of 30 sessions.	BMDL	BMDF; 25(OH)D; LE MMT; BBS	Effective as alendronate.	24 weeks
Liu Hf et 8 al, 2014 ³¹	84	1. PEMFs (n=44) 2. AL (n=40)	62.41 (5.47) 62.63 (4.54)	0/84	PEMFs	3.8 mT, 8-12 Hz, 40min/session for a total of 30 sessions.	BMDL; BMDF	VAS; TUG; BBS	Effective as alendronate.	72 weeks
Shanb et é al, 2017 ³³	68	1. PEMFs (n=25) 2. WBV (n=25) 3. AL (n=18)	63.9 (3.9) 64.1 (4.4) 64.5 (4.03)	23/45	PEMFs	5 mT, 33 Hz, 50 min/session, 2 sessions/week for 16 weeks.	BMDL; BMDF	Serum calcium and vitamin D	Effective in conjunction with pharmacological treatment.	N/A
Shanb et 3 al, 2012 ³⁴	30	1. PEMFs (n=15) 2. Exercise (n=15)	60-70	0/30	PEMFs	5 mT, 33 Hz, 50 min/session, 3 sessions/week for 12 weeks.	BMDL; BMDF	N/A	Effective as exercise.	N/A
Elsisi et 3 al, 2015 ²⁹	30	1. PEMFs (n=15) 2. CRT- Exercise (n=15)	64.73 (3.08) 65.13 (2.44)	0/30	PEMFs	5 mT, 33 Hz, 30 min/session, 3 sessions/week for 12 weeks.	BMDL; BMDF	N/A	More effective than CRT exercise.	N/A
Giordan 4 o et al, 2001 ³⁰	40	1. PEMFs (n=20) 2. Placebo (n=20)	56.3 (4.0) 55.9 (3.1)	0/40	PEMFs	1.2 mT, 100 Hz, 60 min/session, 3 sessions/week for 12 weeks.	BMDL; BMDF	Serum and urinary calcium, phosphate; Serum ALP, osteocaltin and PICP; Urinary hydroxyproline	Not effective in increasing BMD, but effective in stimulating osteogenesis.	1 month
Wu Yc et 4 al, 2014 ³⁵	43	1. PEMFs (n=24) 2. AL (n=19)	59.08 (4.65) 59.53 (5.40)	0/43	PEMFs	3.8 mT, 8-12 Hz, 40min/session for a total of 30 sessions.	TUG; BBS; Balance function	N/A	Effective as alendronate.	N/A

Ashraf et al,	60	1. PEMFs (n=20)	59.85 (2.35)	26/34	PEMFs	4 mT, 33 Hz, 30 min/session, 3	BMDL	N/A	More effective than LLLT and	N/A
2017 ²⁸		2. LLLT (n=20)	60.20 (2.17) 60.00 (2.62)			sessions/week for 12 weeks.			AL group.	
-		3. Med (n=20)								

^aWaveforms; Intensity; Frequency; Duration (weeks).

^bAbbreviations. PEMFs=Pulsed electromagnetic fields, AL=alendronate, WBV=Whole body vibration, CRT=Circuit weight training, LLLT=low-level laser therapy, mT=millitesla, Hz=Hertz, BMDL=lumbar bone mineral density, BMDF=femur bone mineral density, 25(OH)D=serum 25OH vitamin, LE MMT=total lower-extremity manual muscle test, BBS=Berg Balance Scale, VAS=Visual Analogue Scale, N/A=not applicable, TUG=Timed Up and Go, ALP=Alkaline Phosphatase, PICP=Procollagen type I carboxy-terminal propeptide, Med=Medication.





Figure 1. PRISMA flow of studies through the review.



Test for subaroup differences: Not applicable

Figure 2. Forest plot analysis of the effects of PEMFs on BMD at the lumbar (A) and femur neck (B) compared with placebo control. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BMD = Bone Mineral Density; PEMFs = Pulsed Electromagnetic Fields.





Figure 3. Forest plot analysis of the effects of PEMFs on balance function measured by BBS (A) and TUG test (B) compared with placebo control. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BBS = Berg Balance Scale; TUG = Timed Up and Go; PEMFs = Pulsed Electromagnetic Fields.






Figure 4. Forest plot analysis of the effects of PEMFs on BMD at the lumbar (A) and femur neck (B) compared with exercise group. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BMD = Bone Mineral Density; PEMFs = Pulsed Electromagnetic Fields.